Our evolving understanding of the molecular diversity of diffuse mesothelioma and other mesothelial lesions has led to considerable changes in pathology diagnostic practice, including the application of immunohistochemical markers such as BAP1, MTAP, and merlin (NF2), which are surrogates of mutation status. In young patients and/or those without significant asbestos exposure, unusual mesothelioma genetics such as germline mutations, ALK rearrangement, and ATF1 rearrangement should be considered.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- healthcare
- primary care
- signaling pathway
- prognostic factors
- peritoneal dialysis
- oxidative stress
- single molecule
- dna repair
- patient reported outcomes
- high glucose
- cell proliferation
- advanced non small cell lung cancer
- toll like receptor
- patient reported
- middle aged
- tyrosine kinase
- pi k akt